CRIS Current Research Information System

VIANELLI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.960
AS - Asia 3.478
EU - Europa 3.141
AF - Africa 253
SA - Sud America 225
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.066
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.900
SG - Singapore 1.198
CN - Cina 1.035
GB - Regno Unito 734
SE - Svezia 521
VN - Vietnam 512
IT - Italia 506
DE - Germania 436
HK - Hong Kong 280
IN - India 217
RU - Federazione Russa 176
BR - Brasile 153
IE - Irlanda 151
FR - Francia 125
NL - Olanda 96
CI - Costa d'Avorio 83
FI - Finlandia 77
KR - Corea 77
TG - Togo 69
UA - Ucraina 65
ZA - Sudafrica 58
EE - Estonia 56
BG - Bulgaria 42
CA - Canada 40
JO - Giordania 37
JP - Giappone 37
BE - Belgio 36
CH - Svizzera 35
AR - Argentina 25
NG - Nigeria 21
ID - Indonesia 20
AT - Austria 18
PL - Polonia 18
IR - Iran 15
MX - Messico 15
EC - Ecuador 14
TR - Turchia 12
CO - Colombia 11
CZ - Repubblica Ceca 11
BD - Bangladesh 9
SC - Seychelles 9
LT - Lituania 8
PY - Paraguay 8
ES - Italia 7
AU - Australia 6
GR - Grecia 5
PE - Perù 5
RO - Romania 5
TW - Taiwan 5
CL - Cile 4
EG - Egitto 4
IQ - Iraq 4
AZ - Azerbaigian 3
DZ - Algeria 3
IL - Israele 3
LV - Lettonia 3
MK - Macedonia 3
AL - Albania 2
DK - Danimarca 2
ET - Etiopia 2
GT - Guatemala 2
KE - Kenya 2
MA - Marocco 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PK - Pakistan 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BO - Bolivia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GF - Guiana Francese 1
HU - Ungheria 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
NO - Norvegia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 12.066
Salva come PNG Salva come JPEG
Città #
Singapore 785
Southend 635
Ashburn 596
Fairfield 555
Chandler 464
Hong Kong 278
Seattle 241
Woodbridge 236
Cambridge 232
Houston 227
Wilmington 216
Dong Ket 205
Ann Arbor 185
Hefei 174
Santa Clara 173
Princeton 161
Beijing 157
Dublin 149
Boardman 111
Bologna 106
Los Angeles 85
Abidjan 83
Seoul 74
Dallas 73
Lomé 69
Ho Chi Minh City 67
Nanjing 66
Westminster 64
Hanoi 57
Helsinki 57
Padova 54
Bremen 51
Milan 49
Munich 49
New York 49
Berlin 44
Hyderabad 43
Buffalo 42
Sofia 42
Jinan 39
Turin 39
Amman 37
Shenyang 37
Brussels 36
Saint Petersburg 35
Tokyo 35
Cornaredo 32
Jacksonville 32
Bern 31
Redmond 28
Redondo Beach 27
Frankfurt am Main 24
San Diego 24
Guangzhou 20
Changsha 19
Abeokuta 18
Nanchang 18
Zhengzhou 18
Bengaluru 17
London 17
Shanghai 17
Chicago 16
Falls Church 16
Hebei 16
Jakarta 16
Phoenix 16
Hangzhou 14
Toronto 14
Nuremberg 13
Tianjin 13
Des Moines 12
Menlo Park 12
São Paulo 12
Amsterdam 11
Brooklyn 11
Falkenstein 11
Florence 11
Lappeenranta 11
Medford 11
Olalla 11
Redwood City 11
Warsaw 11
Dearborn 10
Fremont 10
Jiaxing 10
Norwalk 10
Orem 10
Rome 10
Boydton 9
Modena 9
Monheim 9
Montreal 9
Mountain View 9
Stockholm 9
Taiyuan 9
Turku 9
Boston 8
Haikou 8
Leawood 8
Ningbo 8
Totale 8.037
Salva come PNG Salva come JPEG
Nome #
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 226
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 205
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 203
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 197
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 195
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 187
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 186
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 186
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 181
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 177
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 176
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 173
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 172
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 170
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 170
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 169
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 169
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 167
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 165
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 164
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 162
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 162
Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. 162
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 160
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 159
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 158
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 154
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 152
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 152
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 150
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 148
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 148
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 147
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 147
A risk prediction score for invasive mold disease in patients with hematological malignancies 144
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly 143
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 142
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 141
Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B 138
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 129
Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies 128
Dexamethasone plus rituximab yieldshigher sustained response rates than dexamethasone monotherapy in adultswith primary immune thrombocytopenia 127
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 125
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 125
Retrospective cohort analysis of liposomal amphotericin b nephrotoxicity in patients with hematological malignancies 125
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 123
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 123
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years 122
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 122
Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray. 121
Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline. 120
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. 120
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 120
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 119
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 119
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 116
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. 115
Resolution of a Pseudomonas aeruginosa outbreak in a hematology unit with the use of disposable sterile water filters. 114
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 114
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. 112
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 112
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 111
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 110
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 109
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 108
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 105
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 105
The CD47 pathway is deregulated in human immune thrombocytopenia 103
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 102
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 102
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 101
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 98
null 98
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 98
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. 97
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 96
null 96
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 92
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 87
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 87
null 86
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 85
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 83
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 75
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 73
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 72
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 71
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 68
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 67
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 66
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 66
Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis 63
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 63
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 63
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 59
Sinonasal risk factors for the development of invasive fungal sinusitis in hematological patients: Are they important? 37
Increased P-selectin plasma levels in patients with thrombotic thrombocytopenic purpura 37
A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase 36
Ticlopidine in the treatment of thrombotic thrombocytopenic purpura: Report of two cases 33
Prompt plasma-exchange treatment and coma reversibility in two patients with thrombotic thrombocytopenic purpura 23
Totale 12.289
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.382
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.382
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021764 0 0 0 0 0 36 39 48 122 66 53 400
2021/20221.577 78 43 91 187 127 71 38 103 53 183 334 269
2022/20231.856 174 270 102 249 122 162 47 125 323 79 125 78
2023/2024554 40 92 45 65 44 95 9 40 18 37 38 31
2024/20252.184 121 278 180 196 284 118 147 101 74 150 109 426
2025/20262.396 409 400 457 379 530 221 0 0 0 0 0 0
Totale 12.342